<DOC>
	<DOCNO>NCT00787917</DOCNO>
	<brief_summary>This study evaluate safety efficacy omalizumab treatment Allergic Bronchopulmonary Aspergillosis ( ABPA ) patient Cystic Fibrosis age 12 year old .</brief_summary>
	<brief_title>An Exploratory Study Assess Multiple Doses Omalizumab Patients With Cystic Fibrosis Complicated Acute Bronchopulmonary Aspergillosis ( ABPA )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Diagnosis Cystic Fibrosis complicate Allergic Bronchopulmonary Aspergillosis ( ABPA ) Oral corticosteroid use ABPA flare Age 12 year old ( except Italy ; ≥ 18 year ) Total serum IgE level ≥ 500 IU/mL History cancer last 10 year . History severe allergic reaction Pregnant lactate woman Prior use Xolair Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Allergic Bronchopulmonary Aspergillosis</keyword>
	<keyword>omalizumab</keyword>
	<keyword>oral corticosteroid use</keyword>
	<keyword>anti-immunoglobulin E</keyword>
</DOC>